💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Arseus to distribute medical cannabis in Germany

Published 12/08/2008, 02:39 AM
Updated 12/08/2008, 02:45 AM
OMEP
-

BRUSSELS, Dec 08 (Reuters) - Medical cannabis will be distributed in Germany by Fagron Germany, a unit of Belgian medical wholesaler Arseus NV, as of today, Arseus said in a statement on Monday.

Fagron Germany has an exclusive license for the import and distribution of medical cannabis, or marijuana, in Germany, Arseus said.

It added that Fagron Nederland has been active in the Netherlands's medical cannabis market since 2003.

An increasing number of German doctors are interested in prescribing medical cannabis to certain patients, Arseus said.

Politicians there have recently decided to make the drug available to patients in some cases, according to the company's statement.

Proponents of the medical use of marijuana say the plant relieves suffering or symptoms from illnesses which include AIDS, glaucoma, cancer and multiple sclerosis. The drug remains illegal, both for medical and recreational purposes, in most of the world.

Arseus's product line includes dental chairs, hospital beds, surgical instruments and pharmaceutical ingredients. The company also offers IT services for the medical industry. Arseus had been a subsidiary of health products distributor Omega Pharma, and listed on the Euronext Brussels and Amsterdam in October 2007. (Reporting by Anne Jolis; Editing by Rupert Winchester)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.